Find Academic Supervisors

Dr. Jason Webber is a Senior Lecturer in Biomedical Sciences at Swansea University Medical School. He holds an honorary position as a Research Fellow at Cardiff University and is a board member of the UK Society for Extracellular Vesicles. His research focuses on extracellular vesicles (EVs), particularly their role in cancer progression and as biomarkers for aggressive tumors like prostate cancer. He completed his PhD at Cardiff University's Institute of Nephrology in 2009 and received a Prostate Cancer UK Career Development Fellowship (2014–2020). Dr. Webber's expertise includes EV biology, tumor microenvironment dynamics, and translational research. He actively contributes to teaching modules such as 'Genetics of Cancer' and 'Advanced Research Topics in Biomedical Science'. His work spans collaborations with institutions like Erasmus MC and the CIC bioGUNE in Spain. Key grants include funding for projects like 'Extracellular Vesicle Glycoproteins for Prostate Cancer Diagnosis (EVGlyProD)' and investigations into EV roles in bone metastasis and rare diseases like tuberous sclerosis complex. His research highlights EVs' dual role as functional mediators of tumor growth and potential biomarkers. Notable achievements include demonstrating EV-HSPG's role in stromal activation and developing methodologies for EV-based diagnostics. Dr. Webber supervises multiple PhD and MSc students, emphasizing mentorship in EV research and cancer biology.

• Extracellular Vesicles (EVs)
• Tumour Microenvironment
• Prostate Cancer
• +6 more

Joe Pitt-Francis is Associate Professor of Computer Science and Tutorial Fellow in Computer Science at St Edmund Hall, University of Oxford . Since 1999 he has tutored Oxford computer-science students and formally became a Tutorial Fellow of St Edmund Hall in 2024. His research lies at the intersection of computational biology and mathematical biology . Using sophisticated numerical techniques he constructs and analyses models of the heart , cancer and blood flow . A central strand of his work is software development for biological simulation; he is an active contributor to Chaste ( Cancer, Heart and Soft-Tissue Environment ), a large-scale C++ library that supports multiscale computational models in physiology and medicine. Across more than 60 peer-reviewed publications since 1998, his work has progressively advanced from foundational software-engineering papers describing Chaste’s architecture to highly-cited studies on cardiac electrophysiology , tumour-induced angiogenesis , microvascular haemodynamics and cell-cycle dynamics under hypoxia . The 2024-2025 corpus shows strong emphasis on multiscale frameworks , open benchmarking , and radiotherapy-induced vascular remodelling , positioning his group at the forefront of translational in-silico oncology. Contact: Email: Joe.Pitt-Francis@seh.ox.ac.uk

• Computational Biology
• Mathematical Biology
• Cardiac Electrophysiology Modelling
• +3 more

Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.

• Radiation Therapy
• Prostate Cancer
• Bladder Cancer
• +9 more

Vivian Li is a Senior Group Leader and Assistant Research Director at The Francis Crick Institute in London, UK, leading a research group focused on intestinal stem cell biology and colorectal cancer mechanisms. Dr. Li earned her PhD from the University of Hong Kong's Department of Pathology in 2008, researching molecular mechanisms of human colonic development and tumorigenesis, for which she received the Gold Medal Prize. She then completed postdoctoral training with Hans Clevers at the Hubrecht Institute in the Netherlands, funded by the Croucher Foundation Fellowship, focusing on Wnt pathway proteomics and intestinal stem cell genes using transgenic mouse models. Her research program investigates how stem cells maintain healthy gut tissue and what goes wrong during cancer development, with particular emphasis on Wnt signaling pathways. Dr. Li's laboratory utilizes advanced organoid technology ('mini-guts') to study stem cell behavior in three-dimensional cultures, gene editing techniques, and state-of-the-art imaging approaches. Her work spans developmental biology, stem cell research, and cancer biology with significant translational implications. Analysis of her recent publications (2022-2025) reveals a strong focus on cancer stemness mechanisms, intestinal regeneration pathways, Wnt signaling components, and innovative organoid modeling approaches for colorectal cancer. Her research consistently bridges basic science with potential clinical applications in gastrointestinal medicine. Gold Medal Prize for PhD thesis Croucher Foundation Fellowship Dr. Li established her independent laboratory at the MRC National Institute for Medical Research in February 2013 and transitioned to the Francis Crick Institute in 2015. Her research aims to develop tumor-specific therapies for bowel cancer and grow replacement human gut tissue for transplantation or drug testing platforms. She leads a multidisciplinary team utilizing cutting-edge techniques including reverse mouse genetics, ex vivo organoid cultures, and advanced genomic and proteomic analyses to investigate stem cell regulation in health and disease. Her laboratory at the Crick Institute operates within the Biological Research Facility and collaborates extensively with other research groups both within the institute and internationally, contributing significantly to understanding intestinal stem cell niche dynamics and cancer development mechanisms.

• Stem Cells
• Tumour Biology
• Developmental Biology
• +6 more

Dr Michael Boemo is an Assistant Professor at the University of Cambridge, holding dual appointments in the Department of Pathology and Department of Genetics. He leads research at the intersection of computational biology, DNA replication, and cancer genomics, developing machine learning tools to analyze replication stress and genomic instability. Academic Background: BA in Mathematics (Rutgers University), PhD in Physics (University of Oxford) Research Focus: Genomic instability in cancer, DNA replication/repair defects, computational modeling using machine learning and high-performance simulations Teaching: Lectures in Natural Sciences Tripos (mathematical biology, genetics, systems biology), module organizer for cancer biology and biological modeling His research group leverages nanopore sequencing and AI to map replication fork dynamics, revealing how stalled forks generate mutations in cancer cells and pathogens. Recent work examines extrachromosomal DNA replication vulnerabilities and transcription-replication conflicts. Dr Boemo collaborates across computational biology and cancer research domains, with publications spanning journals like Nature Methods, Cell, and PLoS Computational Biology. His lab develops tools such as DNAscent for replication fork analysis and explores therapeutic targeting of replication stress.

• Genomic Instability
• DNA Replication and Repair
• Computational Biology
• +5 more

Dimitrios (Dimitris) Anastasiou is a Senior Group Leader at The Francis Crick Institute in London, UK, specializing in cancer metabolism research. Previously, he served as a Group Leader at the Medical Research Council National Institute for Medical Research (NIMR) starting in 2012 before transitioning to the Crick Institute in 2015. His research career includes postdoctoral work and an Instructor position at Beth Israel Deaconess Medical Center and the Department of Systems Biology, Harvard Medical School under Lewis Cantley, where he focused on metabolic reprogramming in cancer. University College London, UK - BSc Molecular Biology (2001) University of Basel, Basel, Switzerland - PhD in Biochemistry (2006) Anastasiou's research centers on understanding how cancer cells generate energy and utilize nutrients differently from normal cells. His laboratory conducts detailed analyses of metabolic pathways in cancer, investigating how tumor cells rewire their metabolism to support rapid growth and evade the body's defenses. His work spans biochemistry, proteomics, computational systems biology, human physiology, and tumor biology, with particular emphasis on identifying metabolic vulnerabilities that could be targeted for cancer therapy. His innovative approaches include developing chemical 'sensors' to monitor metabolic changes in cancer cells over time as tumors develop. Analysis of his recent publications reveals a consistent focus on metabolic regulation in cancer, particularly regarding glycolysis, hypoxia response, amino acid metabolism, and nucleotide biosynthesis. His work frequently examines enzyme regulation (particularly PKM2), metabolic adaptation to environmental stressors, and the intersection between metabolism and signaling pathways. A notable trend is his exploration of how metabolic enzymes function beyond their traditional roles, influencing cellular signaling and gene expression in cancer contexts. Anastasiou has made significant contributions to understanding metabolic reprogramming in cancer, particularly regarding pyruvate kinase M2 regulation, hypoxia responses, and nutrient utilization in tumor microenvironments. His work bridges basic biochemical mechanisms with potential therapeutic applications, focusing on identifying metabolic vulnerabilities in cancer cells that could be exploited for treatment. As a Senior Group Leader at the Crick Institute, Anastasiou leads a research group investigating how metabolism contributes to disease, particularly cancer. His laboratory utilizes a range of techniques including metabolomics, bioinformatics, structural biology, and high-throughput screening to study metabolic pathways. The group's work aims to identify fundamental differences between metabolic pathways in tumors and healthy tissue to discover new therapeutic targets against cancer.

• Cancer Metabolism
• Metabolic Reprogramming
• Biochemistry & Proteomics
• +3 more

Helen Byrne is a Professor of Applied Mathematics at the University of Oxford and a Tutorial Fellow at Keble College. Her academic roles include former Examiner for Final Honour School Mathematics, Associate Head of Department for Planning and Equality and Diversity, and Director of Equality and Diversity in the university’s MPLS Division. DPhil MSc BA/MA Her research focuses on developing mathematical and computational models to study biomedical systems, particularly solid tumours, wound healing, and tissue engineering. She aims to uncover mechanisms behind biological phenomena and derive novel mathematical insights from these models. Recent publications highlight her work in tumor-immune interactions, atherosclerosis, antibody dynamics, and radiation therapy, employing techniques like spatial modeling, agent-based simulations, and multiscale approaches. Her research bridges theoretical mathematics and practical biomedical challenges. 2019: Leah Edelstein-Keshet Prize (Senior Award), Society for Mathematical Biology 2020: Fellow of the Society for Mathematical Biology Helen Byrne has supervised numerous students and researchers, contributing to mathematical biology and biomedical modeling. Her teaching includes courses on multivariable calculus, applied partial differential equations, and advanced mathematical biology.

• Mathematical Biology
• Computational Biology
• Tumour Modeling
• +5 more

Sophia Bano is an Assistant Professor in Robotics and Artificial Intelligence at the Department of Computer Science, University College London (UCL), since November 2022. She is affiliated with the Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS), Surgical Robot Vision group, UCL Robotics Institute, and the Centre for Artificial Intelligence. Previously, she was a Senior Research Fellow at WEISS, contributing to the GIFT-Surg project. Her research focuses on AI-driven techniques for context awareness, navigation, and surgical robotics in minimally invasive procedures, including endoscopic workflow analysis, 3D reconstruction, and surgical vision systems. Education: BEng in Mechatronics Engineering (NUST, Pakistan), MSc in Electrical Engineering (NUST), MSc in Computer Vision and Robotics (Erasmus Mundus VIBOT), PhD from Queen Mary University of London and Technical University of Catalonia (Erasmus Mundus Fellowship). Post-doctoral work at University of Dundee (EPSRC ACE-LP project) and Imperial College London (ERC STING project). Research interests include computer vision for surgery, medical imaging, surgical robotics, and AI in healthcare. She leads the UKRI EPSRC-funded 'AI-enabled Decision Support in Pituitary Surgery' project and contributed to the GIFT-Surg and CARES projects. Publications span 3D reconstruction in fetoscopy, surgical workflow recognition, and AI models for medical imaging. Awards include the IJCARS-MICCAI Best Paper Award (2020) and the Best Innovation Award at the 2022 Surgical Robot Challenge. She organizes conferences like EndoVis and serves as a reviewer for journals like IEEE Transactions on Medical Imaging and MICCAI.

• Computer Vision
• Surgical Robotics
• Medical Imaging
• +3 more

Dr. Masahiro Ono is a Reader in Immunology at Imperial College London's Department of Life Sciences, within the Faculty of Natural Sciences. He leads research on T-cell regulation, focusing on autoimmunity, infections, and cancer. His lab pioneered the Tocky system, using Fluorescent Timer proteins to study T-cell activity dynamics in vivo. Dr. Ono holds affiliations with the CRUK Convergence Science Centre, Infection and Immunity, and Integrative Systems Biology. His academic journey includes an MD from Kyoto University (1993-1999) and a PhD in regulatory T cells (2002-2006). He was awarded a HFSP Fellowship (2009) and BBSRC David Phillips Fellowship (2012), establishing his UCL lab before joining Imperial in 2015. Research Interests : Dr. Ono's work bridges immunology, genomics, and systems biology. His lab explores T-cell activation mechanisms, tumor immunology, and bioinformatics tools for single-cell analysis. Key innovations include the Tocky system for real-time cell kinetics tracking and integrative approaches like GatingTree for cytometry data analysis. Awards : HFSP Fellowship (2009) BBSRC David Phillips Fellowship (2012) Grants & Advising : Dr. Ono's grants have supported projects on viral latency, tumor microenvironment modulation, and immune checkpoint therapies. His lab actively collaborates on translational research, though specific grant details are not listed here. Labs & Teams : His lab at Imperial focuses on Tocky-based technologies and interdisciplinary convergence science through the CRUK Centre. Collaborations span virology, oncology, and bioengineering to address unmet clinical needs in immunotherapy.

• Immunology
• Systems Biology
• Genomics
• +4 more

Professor Michael D. Jenkinson holds the Sir John Fisher / RCS England Chair of Surgical Trials at the University of Liverpool , where he is also Professor of Neurosurgery. His work focuses on meningioma management, brain metastases, and interventional clinical trials, with funding from MRC, Brain Tumour Charity, and NIHR. PhD in Neuroscience (Imaging and Biology of Oligodendroglial Tumours) Consultant Neurosurgeon at The Walton Centre (2010–present) Chief Investigator on NIHR-funded trials: ROAM, STOP 'EM, SPRING, ReStart Research Interests: Meningioma growth modeling and personalized monitoring Seizure prophylaxis in neurosurgery Surgical trials methodology Quality of life assessments in neuro-oncology Leadership Roles: Chair, SBNS Academic Committee Chair, EORTC Meningioma Committee Member, NIHR HTA Prioritisation Committee Co-Investigator on PROSSPER and FUTURE GB trials

• Neurosurgery
• Neuro-Oncology
• Meningioma Management
• +4 more

Dr. William M Holmes is a Senior Research Fellow and Senior MRI Physicist at the University of Glasgow's School of Psychology & Neuroscience, affiliated with the Glasgow Experimental MRI Centre. He holds a PhD in Physical Chemistry from the University of Nottingham and specializes in advancing MRI techniques for biomedical and physical sciences. His work bridges physics, neuroscience, and clinical applications, with a focus on cerebral blood flow imaging, glymphatic system dynamics, and disease modeling in rodents. Key roles: MRI method development, neuroimaging biomarkers, porous media analysis Leadership: Glasgow Experimental MRI Centre Research interests emphasize novel MRI applications in stroke, neurological disorders, and material science. Over 80 peer-reviewed publications demonstrate contributions to perfusion imaging, biofilm dynamics, and translational MRI techniques. Recent projects include: Quantitative arterial spin labeling methods Glymphatic system's role in multiple sclerosis Non-invasive rodent disease modeling

• MRI Technology
• Biomedical Imaging
• Physical Chemistry
• +3 more

Ted Hupp is Chair of Cancer Research and Professor of Cancer Research at the University of Edinburgh's Institute of Genetics and Cancer, where he leads the Edinburgh Cancer Research Centre. His laboratory focuses on developing next-generation technologies for drug discovery in cancer, with particular emphasis on cancers of unmet clinical need including oesophageal adenocarcinoma and sarcomas. Dr. Hupp's research interests center on understanding cancer progression pathways, particularly those involving p53 mutation, which is one of the most common genetic changes in cancer development. His lab employs biophysical, biochemical, and proteomic approaches to develop novel molecular insights into clinically relevant cancer progression pathways. His work spans three main research programs: drugging protein-protein interactions to activate the p53 tumour suppressor, investigating the secretory pathway as a driver in oesophageal cancer, and developing immunotherapeutics, monoclonal antibodies, and vaccinology platforms. Analysis of his recent publications reveals a strong focus on proteogenomics, protein science, and translational applications. His work increasingly integrates canine models for comparative medicine, proteomic approaches to understand protein synthesis dynamics, and novel antibody development for cancer therapeutics. The research shows a clear trajectory toward personalized cancer immunotherapies and vaccine development based on neoantigen landscapes. Professor Hupp has successfully secured funding from major organizations including BBSRC, Medical Research Scotland, The Technology Strategy Board, British Council, European Union Development Fund, Wellcome Trust, and Cancer Research UK. His current projects include optimization of synthetic antibody libraries, selection and characterization of anti-peptide synthetic antibodies, CRISPR-based genome-wide approaches for identifying vulnerabilities in canine oral melanoma, and the KATY project focused on clinical knowledge systems. He advises multiple PhD students including Kamila Pawlicka, Estefania Esposito, Vanessza Fentor, Sinem Gul, and Mishal Tariq. His research group collaborates extensively with scientists across the University of Edinburgh, Cambridge University, Masaryk Cancer Institute in Brno, and the Indian Institute for Science in Bangalore. The lab maintains expertise in protein science, post-translational modifications, phage antibody libraries, RNA editing, p53 pathway science, and proteogenomics.

• Cancer Research
• p53 Pathway Science
• Protein-Protein Interactions
• +7 more

Brigitta Stockinger is a distinguished Professor at the Francis Crick Institute, leading research in the Division of Molecular Immunology. With a career spanning over three decades, she has established herself as a leading authority in immunology, particularly in the study of T cell biology and the aryl hydrocarbon receptor (AHR) pathway. PhD in Biology from the University of Mainz Postdoctoral training in London, Cambridge, and Heidelberg Member of the Basel Institute for Immunology (1985-1991) Group leader at MRC National Institute for Medical Research (1991-present, now part of Francis Crick Institute) Head of Division of Molecular Immunology (2010-present) Professor Stockinger's research has evolved from studying immune tolerance using T cell receptor transgenic mouse models to pioneering work on immunological memory with CD4 memory T cells. Her lab made seminal discoveries regarding Th17 cell differentiation factors, which led to groundbreaking research on the aryl hydrocarbon receptor (AHR) as an environmental sensor in the immune system. Her work spans fundamental immunology, infection responses, inflammation, and the intersection of environmental factors with immune regulation. Analysis of her extensive publication record (over 65 Crick publications) reveals a strong focus on Immunology (38 publications), followed by Model Organisms (12), Genetics & Genomics (10), and Tumour Biology (9). Her most influential work appears in top journals including Nature (5 papers), Nature Immunology (6 papers), and Immunity (6 papers), demonstrating the high impact of her research on understanding T cell plasticity, AHR signaling, and mucosal immunity. Fellow of the Academy of Medical Sciences (2005) EMBO fellow (2008) Fellow of the Royal Society (2013) ERC Advanced Investigator grant (2009) Wellcome Senior Investigator Grant (2013) CRUK grant (2015) Wellcome Investigator Grant (2018) Professor Stockinger's laboratory investigates how environmental factors influence immune responses through the AHR pathway, with particular emphasis on intestinal immunity, inflammation, and host-microbe interactions. Her work has significant implications for understanding inflammatory bowel diseases, infection responses, and the role of dietary components in immune regulation. She has established numerous collaborations across the Francis Crick Institute and maintains active research programs examining AHR's role in both innate and adaptive immunity.

• Immunology
• Molecular Immunology
• T cell biology
• +5 more

Dr. Adrian Biddle is a Reader in Cancer Biology at Queen Mary University of London, affiliated with the Centre for Cell Biology and Cutaneous Research within the Faculty of Medicine and Dentistry. He specializes in understanding non-genetic cellular heterogeneity in oral cancer and its implications for tumor spread and therapeutic resistance. Education: BSc in Biochemistry (University of Bristol), PhD in Nuclear Reprogramming (Cambridge University) Career: Postdoctoral Fellow at Blizard Institute (2008-2017), Principal Investigator since 2017, promoted to Reader in 2024 Research: Focuses on cancer stem cell plasticity in oral squamous cell carcinoma, molecular mechanisms of therapeutic resistance, and development of animal-free in vitro models Awards: NC3Rs David Sainsbury fellowship (2012), DHT lectureship in animal replacement science (2017) Supervision: Primary supervisor for five PhD students Collaborations: NC3Rs-funded tumor-on-chip projects, MRC-supported 3D modeling, Oracle Cancer Trust partnerships Teaching: Contributes to Stem Cells and Regenerative Medicine MSc course

• Non-genetic cellular heterogeneity in oral cancer
• Cancer stem cell biology
• Therapeutic resistance mechanisms
• +3 more

Dr. Zoi Diamantopoulou is a Beatson Research Fellow at the Cancer Research UK Scotland Institute (School of Cancer Sciences), Glasgow. Previously, she held Senior Postdoctoral Marie Curie Fellowships at ETH Zürich and University of Basel. Her research focuses on the interplay between circadian rhythms and cancer metastasis, particularly through circadian regulation of Circulating Tumour Cells (CTCs). Education: PhD in Cellular Biology (2010), University of Patras, Greece BSc in Biology (2005), University of Patras, Greece Her work employs in vivo mouse models, microfluidics, genetic engineering, and next-generation sequencing to explore how circadian disruptions influence metastatic progression. She also investigates chronotherapy for optimized drug administration and analyzes patient blood samples to identify circadian-related molecular vulnerabilities. Scientific Awards: 2021 Marie Skłodowska-Curie Postdoctoral Fellowship 2018 The BACR Chris Marshall Prize for Cell Signalling Lab Members: Senior Scientific Officer Gurman Pall, PhD Student Sara Ortega.

• Metastasis
• Circadian Rhythm
• Cancer Biology
• +3 more